ATAZANAVIR

Product NDC
70518-2832
11-digit product format
705182832
Labeler code
70518
Product ID
70518-2832_d76fb938-efeb-67a9-e053-2995a90a7cfc
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Atazanavir
Dosage form
CAPSULE, GELATIN COATED
Route
ORAL
Labeler
REMEDYREPACK INC.
Application
ANDA200626
Marketing category
ANDA
Marketing start
2020-08-10
Marketing end
0000-00-00
Substance
ATAZANAVIR SULFATE
Active strength
300 mg/1
Pharmacologic classes
Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inhibitors [MoA], UGT1A1 Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2023-12-31
Current FDA listing
Historical FDA.report record

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
70518-2832-02022-02-08C16284748780-1d6a99b39-935b-a426-e053-dadaa90af4c2bb717c4d-bd11-49af-8ec3-1efdce33a245
70518-2832-02022-01-28C16284748780-1d6a99b39-935b-a426-e053-dadaa90af4c2bb717c4d-bd11-49af-8ec3-1efdce33a245

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startMarketing endSampleExclude flagStatus
70518-2832-07051828320030 CAPSULE, GELATIN COATED in 1 BLISTER PACK (70518-2832-0) 2020-08-100000-00-00NoNoCurrent